Kaken Pharmaceutical Co., Ltd. (TYO:4521)
Japan · Delayed Price · Currency is JPY 4,135.00
-15.00 (-0.36%)
Jan 21, 2026, 3:30 PM JST
Kaken Pharmaceutical Revenue
Kaken Pharmaceutical had revenue of 20.49B JPY in the quarter ending September 30, 2025, a decrease of -38.13%. This brings the company's revenue in the last twelve months to 82.02B, down -5.99% year-over-year. In the fiscal year ending March 31, 2025, Kaken Pharmaceutical had annual revenue of 94.04B with 30.52% growth.
Revenue (ttm)
82.02B
Revenue Growth
-5.99%
P/S Ratio
1.92
Revenue / Employee
72.84M
Employees
1,126
Market Cap
157.15B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 94.04B | 21.99B | 30.52% |
| Mar 31, 2024 | 72.04B | -940.00M | -1.29% |
| Mar 31, 2023 | 72.98B | -3.05B | -4.01% |
| Mar 31, 2022 | 76.03B | 1.06B | 1.41% |
| Mar 31, 2021 | 74.98B | -14.25B | -15.97% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Takeda Pharmaceutical Company | 4.42T |
| Otsuka Holdings | 2.42T |
| Astellas Pharma | 2.01T |
| Daiichi Sankyo Company | 1.98T |
| Chugai Pharmaceutical | 1.21T |
| Terumo | 1.06T |
| Olympus | 977.65B |
| HOYA Corporation | 892.50B |
Kaken Pharmaceutical News
- 10 months ago - Top 3 Health Care Stocks That May Crash In Q2 - Benzinga
- 1 year ago - Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - Benzinga